MedImmune’s CAIV-T Influenza Vaccine
November 1, 2004 by admin · Leave a Comment
On November 1, 2004 MedImmune announced that enrollment in its Phase 3 CAIV-T influenza vaccine trial had been completed. This pivotal trial is designed to compare the company’s nasally administered cold-adapted vaccine to the standard injectable vaccine in 8,492 children between 6 and 59 months of age. CAIV-T is refrigerator stable and is regarded by [...]
ID Biomedical’s FluInsure Influenza Vaccine
July 20, 2004 by admin · Leave a Comment
FluInsure™ On July 20 2004, ID Biomedical released preliminary data regarding FluInsure™ from its field efficacy study. Carried out during the 2003-2004 flu season at 28 sites throughout Canada, this study involved 1,349 healthy participants aged 18 to 64. A single dose of the nasally delivered, non-living vaccine had 67% efficacy (3/451 vs. 9/443 placebo) [...]
VaxGen’s rPA102 Recombinant Anthrax Vaccine
April 15, 2004 by admin · Leave a Comment
On April 15, 2004 VaxGen, Inc. announced that it had started the Phase II clinical testing of rPA102, its recombinant anthrax vaccine. VaxGen indicated that this 13-month trial is one of two studies under a $80.3 million agreement with the NIH’s National Institute of Allergy and Infectious diseases. The purpose of this study, involving 480 [...]
OraQuick Rapid HIV Antibody Test
March 26, 2004 by admin · Leave a Comment
On March 26, 2004 OraSure Technologies, Inc. announced that it has received U.S. Food and Drug Administration approval of its OraQuick® Rapid HIV Antibody Test for use with oral fluid. This would make OraQuick the first such test to receive FDA approval in the U.S. The FDA-approved OraSure® Oral Specimen Collection Device is a generic [...]